CN104203246A - 治疗妇科疾病的方法 - Google Patents

治疗妇科疾病的方法 Download PDF

Info

Publication number
CN104203246A
CN104203246A CN201380014168.1A CN201380014168A CN104203246A CN 104203246 A CN104203246 A CN 104203246A CN 201380014168 A CN201380014168 A CN 201380014168A CN 104203246 A CN104203246 A CN 104203246A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cdb
applicable
receptor modulator
progesterone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380014168.1A
Other languages
English (en)
Chinese (zh)
Inventor
J-P·戈特兰
V·布雅科
E·卢马耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Preglem SA
Original Assignee
Preglem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem SA filed Critical Preglem SA
Publication of CN104203246A publication Critical patent/CN104203246A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380014168.1A 2012-03-23 2013-03-22 治疗妇科疾病的方法 Pending CN104203246A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
US61/614,785 2012-03-23
EP12160956.4 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (1)

Publication Number Publication Date
CN104203246A true CN104203246A (zh) 2014-12-10

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014168.1A Pending CN104203246A (zh) 2012-03-23 2013-03-22 治疗妇科疾病的方法

Country Status (18)

Country Link
US (1) US10441534B2 (enExample)
EP (3) EP2641602A1 (enExample)
JP (2) JP2015514700A (enExample)
KR (1) KR20140138824A (enExample)
CN (1) CN104203246A (enExample)
AU (1) AU2013236960B2 (enExample)
CA (1) CA2864073A1 (enExample)
CO (1) CO7111317A2 (enExample)
EA (1) EA031488B1 (enExample)
GE (1) GEP201706696B (enExample)
HK (1) HK1199827A1 (enExample)
MX (1) MX369520B (enExample)
MY (1) MY172530A (enExample)
NZ (1) NZ630011A (enExample)
SG (1) SG11201404921QA (enExample)
TW (2) TW201400121A (enExample)
WO (1) WO2013140372A1 (enExample)
ZA (1) ZA201407575B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095418A1 (en) * 2008-01-29 2009-08-06 Erin Gainer Use of ulipristal for treating uterine fibroids
US20100190758A1 (en) * 2007-04-20 2010-07-29 Prelem S.A. Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
KR101229701B1 (ko) 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
LT2249757T (lt) * 2008-02-04 2017-09-25 Ferring B.V. Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190758A1 (en) * 2007-04-20 2010-07-29 Prelem S.A. Progesterone Antagonist and Selective Progesterone Modulator in the Treatment of Excessive Uterine Bleeding
WO2009095418A1 (en) * 2008-01-29 2009-08-06 Erin Gainer Use of ulipristal for treating uterine fibroids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. B. COPPERMAN等: "Transitioning from intra-muscular progesterone to combination oral and vaginal progesterone prior to the luteo-placetal shift does not diminish ART success", 《FERTILITY AND STERILITY》 *
VLATKA TOMIC 等: "Oral micronized progesterone combined with vaginal progesterone gel for luteal support", 《GYNECOLOGICAL ENDOCRINOLOGY》 *

Also Published As

Publication number Publication date
KR20140138824A (ko) 2014-12-04
CA2864073A1 (en) 2013-09-26
AU2013236960B2 (en) 2017-11-23
TW201832767A (zh) 2018-09-16
GEP201706696B (en) 2017-07-10
JP2015514700A (ja) 2015-05-21
HK1199827A1 (en) 2015-07-24
MX2014011487A (es) 2015-01-12
MX369520B (es) 2019-11-11
TW201400121A (zh) 2014-01-01
US10441534B2 (en) 2019-10-15
JP2018109025A (ja) 2018-07-12
EP2641602A1 (en) 2013-09-25
CO7111317A2 (es) 2014-11-10
ZA201407575B (en) 2015-12-23
NZ630011A (en) 2016-12-23
US20150038476A1 (en) 2015-02-05
WO2013140372A1 (en) 2013-09-26
MY172530A (en) 2019-11-29
EP2827873A1 (en) 2015-01-28
EA031488B1 (ru) 2019-01-31
AU2013236960A1 (en) 2014-09-25
SG11201404921QA (en) 2014-10-30
EA201491614A1 (ru) 2015-01-30
EP3363500A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
CN102458386B (zh) 用于紧急避孕的药物组合物
KR102127348B1 (ko) 항-프로게스틴의 경질 전달을 위한 제제 및 방법
EP2658545B1 (en) Treatment of pain associated with dislocation of basal endometrium
TWI445537B (zh) 治療子宮類纖維瘤之方法
JP2011510949A5 (enExample)
JP2018109025A (ja) 婦人科疾患の治療方法
CN106232107B (zh) 用于抗孕激素的阴道递送的制剂和方法
US20190262361A1 (en) Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
HK1188939A (zh) 基底子宫内膜异位相关疼痛的治疗
HK1206622B (zh) 经阴道递送抗孕素的调配物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1199827

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1199827

Country of ref document: HK